It looks like you are using an older version of Internet Explorer which is not supported. We advise that you update your browser to the latest version of Microsoft Edge, or consider using other browsers such as Chrome, Firefox or Safari.

This educational website is developed and funded by Novartis Pharmaceuticals UK Limited for UK healthcare professionals and other relevant decision makers. If you are a member of the public, please click here (Novartis-owned site).

Explore a range of educational resources designed to support understanding and management of elevated lipoprotein(a) [Lp(a)]. From patient materials to expert-led case studies and discussions addressing common questions and misconceptions, these resources provide practical insights to help inform testing, communication and clinical decision-making.

Lp(a) patient materials

Help your patients make sense of their Lp(a) result. Share this leaflet with them to use as a take-home resource at diagnosis or review. Please download this patient leaflet before sending it to patients. Please do not direct patients to this webpage or website as it is intended for healthcare professions and other relevant decision makers only.

Download now
understanding lipoproteina

Demystifying Lp(a): A Clinician’s Approach with a Real-World Case Study - Alison Pottle

Alison Pottle, Nurse Consultant at Royal Brompton and Harefield NHS Foundation Trust, outlines the role of Lp(a) as an independent cardiovascular risk factor and the importance of targeted testing.

This video covers key patient groups, practical approaches to management, and how addressing overall cardiovascular risk remains central to care. A case study highlights the role of lipoprotein apheresis in selected patients with very high Lp(a), alongside the challenges of access within the UK.

Click play, then use the menu icon in the top-left corner of the player to access video chapters and jump directly to topics of interest

Navigating Elevated Lp(a): A Clinician’s Approach with a Real-World Case Study - Dr Ahai Luvai

Click play, then use the menu icon in the top-left corner of the player to access video chapters and jump directly to topics of interest

Dr Ahai Luvai, Consultant in Clinical Biochemistry & Metabolic Medicine (The Newcastle upon Tyne Hospitals NHS Foundation Trust), outlines the clinical value of Lp(a) testing in identifying patients at increased cardiovascular risk. 

This video highlights priority groups for testing, practical considerations for accurate measurement, and the role of Lp(a) in conditions such as premature cardiovascular disease and aortic valve stenosis.

Navigating Elevated Lp(a): A Clinician’s Approach with a Real-World Case Study - Dr Paul Downie

Dr Paul Downie, Consultant Chemical Pathologist (The University Hospitals of Bristol and Weston NHS Foundation Trust), explores the role of Lp(a) measurement across both secondary and primary prevention settings. This video outlines key patient groups for testing, including those with premature cardiovascular disease, strong family history, or genetic dyslipidaemias, as well as its value in refining risk in borderline cases.

Through the discussion of a real patient case study, it also highlights practical considerations for implementation, patient communication, and the use of Lp(a) to inform treatment decisions and cascade screening.

Click play, then use the menu icon in the top-left corner of the player to access video chapters and jump directly to topics of interest

Navigating Elevated Lp(a): A Clinician’s Approach with a Real-World Case Study - Professor Dev Datta

Click play, then use the menu icon in the top-left corner of the player to access video chapters and jump directly to topics of interest

A case study presented by Professor Dev Datta, Consultant in Metabolic Medicine (Cardiff and Vale University Health Board), exploring the role of Lp(a) in cardiovascular risk assessment. 

This video highlights key patient groups for testing, demonstrates the clinical impact of markedly elevated Lp(a) despite controlled low-density lipoprotein cholesterol (LDL-C), and outlines practical approaches to patient communication.

Demystifying Lp(a): Alison and Paul Address FAQs and Myths - Dr Paul Downie and Alison Pottle

Dr Paul Downie and Alison Pottle address frequently asked questions and common misconceptions around Lp(a), focusing on its role in cardiovascular risk assessment and clinical practice.

This discussion covers who to test, how to interpret results, and why management should focus on optimising overall cardiovascular risk, particularly LDL-C reduction. It also highlights the importance of clear patient communication, standardised testing approaches, and coordinated care across specialties and primary care.

Click play, then use the menu icon in the top-left corner of the player to access video chapters and jump directly to topics of interest

Demystifying Lp(a): Ahai and Dev Address FAQs and Myths - Dr Ahai Luvai and Professor Dev Datta

Click play, then use the menu icon in the top-left corner of the player to access video chapters and jump directly to topics of interest

Dr Ahai Luvai and Professor Dev Datta discuss key questions and common misconceptions around Lp(a), highlighting its role as a genetically determined and highly atherogenic cardiovascular risk factor.

This video covers when to test, how to interpret results, and the importance of intensifying overall risk management in patients with elevated Lp(a). It also explores practical challenges around testing, guideline thresholds, and considerations for cascade screening and specialist interventions.

UK | July 2026 | FA-11687483

lpa footer logo

This site is intended for UK healthcare professionals and other relevant decision makers only.

This website is part of a programme that is created and funded by Novartis Pharmaceuticals UK Limited. Novartis Pharmaceuticals UK Limited is a private limited liability company registered in England and Wales under number 119006. Registered office 2nd Floor, The WestWorks Building, White City Place, 195 Wood Lane, London, W12 7FQ. 
Use of this website is governed by our Terms of Use and the Cookies and Privacy Policy.

©2026 Novartis Pharmaceuticals UK Ltd - UK | July 2026 | FA-11687294.

Terms of use | Cookies and Data Privacy | Cookie Settings